Broad spectrum antiviral nucleosides-Our best hope for the future.

Autor:	Seley-Radtke KL; Department of Chemistry & Biochemistry, University of Maryland, Baltimore County, Baltimore, MD, United States., Thames JE; Department of Chemistry & Biochemistry, University of Maryland, Baltimore County, Baltimore, MD, United States., Waters CD 3rd; Department of Chemistry & Biochemistry, University of Maryland, Baltimore County, Baltimore, MD, United States.
Jazyk:	angličtina
Zdroj:	Annual reports in medicinal chemistry [Annu Rep Med Chem] 2021; Vol. 57, pp. 109-132. Date of Electronic Publication: 2021 Oct 29.
DOI:	10.1016/bs.armc.2021.09.001
Abstrakt:	The current focus for many researchers has turned to the development of therapeutics that have the potential for serving as broad-spectrum inhibitors that can target numerous viruses, both within a particular family, as well as to span across multiple viral families. This will allow us to build an arsenal of therapeutics that could be used for the next outbreak. In that regard, nucleosides have served as the cornerstone for antiviral therapy for many decades. As detailed herein, many nucleosides have been shown to inhibit multiple viruses due to the conserved nature of many viral enzyme binding sites. Thus, it is somewhat surprising that up until very recently, many researchers focused more on "one bug one drug," rather than trying to target multiple viruses given those similarities. This attitude is now changing due to the realization that we need to be proactive rather than reactive when it comes to combating emerging and reemerging infectious diseases. A brief summary of prominent nucleoside analogues that previously exhibited broad-spectrum activity and are now under renewed interest, as well as new analogues, that are currently under investigation against SARS-CoV-2 and other viruses is discussed herein. (Copyright © 2021 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu